AbbVie

Open: 143.1 Close: 143.72 Change: 0.62

How to get informed about AbbVie Company Inc quickly using an AI.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, short, recent, trading, Investors, hop, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie closed the most recent trading day at $137.68, moving +0.81% from the previous trading session. The companys next earnings release is expected to be July 27, 2023.

Today's News

Shares are up today. AbbV : 144.01 (+0.19%) BEP : 29.65 (-1.23%) BEPC : 31.78 (-2.34%) BIP : 35.93 (-0.67%) BipC : 47.05 (+1.44%) AbbVie closed the most recent trading day at $137.68, moving +0.81% from the previous trading session. Investors will be hoping for strength from Abbvie as it approaches its next earnings release, which is expected to be July 27, 2023. Investors should also note any recent changes to analyst estimates. AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. Humira is a key determinant of companys earnings performance over the next three years. AbbVie has announced that the first patient has been dosed in the Phase III Step-Up HS study evaluating upadacitinib in adults and adolescents with hidradenitis suppurativa (HS) The study will involve both adults and. adolescents and Abbvie hopes to recruit 1328 patients across 275 sites worldwide. AbbVies short percent of float has fallen 7.81% since its last report. Peer group average for short interest as a percentage of float is 3.62%, which means the company has less short interest. Abbvie Inc is Overvalued by 14% compared to the current market price of 144.12 USD. The intrinsic value of one ABBV stock under the Base Case scenario is 124.03 USD. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies oncology collaboration. If approved, epcoritmab will be marketed under the brand name TEPKINLY.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Abbvie, short, recent, trading, Investors, hop, and the most common words in the summary are: abbvie, stock, market, abbv, inc, price, news, . One of the sentences in the summary was: AbbVie closed the most recent trading day at $137.68, moving +0.81% from the previous trading session. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #abbv #inc #price #news.